EUVIMEDEUVIMED entdecken
Crossref

Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4

Tingting Yang, Dai Shi iD, Qingyu Lin, Hua Shen, Hui Tan, Yuxia Liu, Hongcheng Shi, Dengfeng Cheng iD

Molecular Pharmaceutics · 06.05.2024 · 21 (5) · 2415-2424

DOI: 10.1021/acs.molpharmaceut.3c01221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 12.04.2024. Verfasst von Tingting Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Medical Imaging, Shanghai 200032, China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Coordination Complexes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, Shanghai Rising-Star Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemokines and chemokine receptors are indispensable to play a key role in the development of malignant tumors. As one of the most widely expressed chemokine receptors, chemokine (C-X-C motif) receptor 4 (CXCR4) has been a popular research focus. In most tumors, CXCR4 expression is significantly upregulated. Moreover, integrated nuclide diagnosis and therapy targeting CXCR4 show great potential. [68Ga]Ga-pentixafor, a radioligand targeting CXCR4, exhibits a strong affinity for CXCR4 both in vivo and in vitro. However, [177Lu]Lu-pentixather, the therapeutic companion of [68Ga]Ga-pentixafor, requires significant refinement to mitigate its pronounced hepatic biodistribution. The objective of this study was to synthesize theranostic molecular tracers with superior CXCR4 targeting functions. The Daudi cell line, which highly expressed CXCR4, and the MM.1S cell line, which weakly expressed CXCR4, were used in this study. Based on the pharmacophore cyclo (-d-Tyr-n-me-d-Orn-l-Arg-L-2-NAL-Gly-) (CPCR4) of pentixafor, six tracers were synthesized: [124I]I-1 ([124I]I-CPCR4), [99mTc]Tc-2 ([99mTc]Tc-HYNIC-CPCR4), [124I]I-3 ([124I]I-pentixafor), [18F]AlF-4 ([18F]AlF-NETA-CPCR4), [99mTc]Tc-5 ([99mTc]Tc-MAG3-CPCR4) and [124I]I-6 ([124I]I-pentixafor-Ga) and their radiochemical purities were all higher than 95%. After positron emission tomography (PET)/single-photon emission computed tomography (SPECT) imaging, the [124I]I-6 group exhibited the best target-nontarget ratio. At the same time, comparing the [68Ga]Ga-pentixafor group with the [124I]I-6 group, we found that the [124I]I-6 group had a better target-nontarget ratio and lower uptake in nontarget organs. Therefore, compound 6 was selected for therapeutic radionuclide (131I) labeling, and the tumor-bearing animal models were treated with [131I]I-6. The volume of the tumor site was significantly reduced in the treatment group compared with the control group, and no significant side effects were found. [124I]I-6 and [131I]I-6 showed excellent affinity for targeting CXCR4, and they showed great potential for the integrated diagnosis and treatment of tumors with high CXCR4 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Coordination ComplexesAnimalsHumansMiceCell Line, TumorTissue DistributionRadiopharmaceuticalsPeptides, CyclicMolecular ProbesGallium RadioisotopesMice, NudeTheranostic NanomedicineFemale

Stichwörter der Autor:innen

CXCR4[124I/131I]I-pentixafor-Gamicro-PET/CTmicro-SPECT/CTtheranostic

Substanzen

Receptors, CXCR468Ga-pentixaforCXCR4 protein, humanRadiopharmaceuticalsPeptides, CyclicMolecular ProbesGallium RadioisotopesCoordination Complexes

Autor:innen und Institutionen

  • Shanghai Institute of Medical Imaging, Shanghai 200032, China.
  • Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Department of Applied Chemistry, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.

ORCID-Profile: Dai Shi, Dengfeng Cheng

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Shanghai Rising-Star Program
  • Clinical Research Project of Zhongshan Hospital

Zitieren

APA

Yang, T., Shi, D., Lin, Q., Shen, H., Tan, H., Liu, Y., Shi, H., & Cheng, D. (2024). Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4. Molecular Pharmaceutics, 21(5), 2415-2424. https://doi.org/10.1021/acs.molpharmaceut.3c01221

Vancouver

Yang T, Shi D, Lin Q, Shen H, Tan H, Liu Y, et al. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4. Molecular Pharmaceutics. 2024;21(5):2415-2424. doi:10.1021/acs.molpharmaceut.3c01221

BibTeX
@article{Yang2024,
  author = {Yang, Tingting and Shi, Dai and Lin, Qingyu and Shen, Hua and Tan, Hui and Liu, Yuxia and Shi, Hongcheng and Cheng, Dengfeng},
  title = {Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  volume = {21},
  number = {5},
  pages = {2415--2424},
  doi = {10.1021/acs.molpharmaceut.3c01221}
}
Kostenlos starten →